Low Late Loss

  • Lower level of late loss achieved in the LEADERS trial with the BioMatrix Flex™ (Biolimus A9™) eluting stent at 9 months compared to the Cypher® Select™ stent6
  • In Stent late loss in LEADERS = 0.13mm6


Highest lipophilicity of the common limus drugs1

  • Minimizes systemic exposure and reduces the drug circulating in the bloodstream
  • Due to high lipophilicity, the drug is rapidly absorbed by tissue


> More details about Biolimus A9™

11184-000-EN - Rev.03 + 10801-000-EN - Rev.05 + 11881-000-EN - Rev.04
BioMatrix NeoFlex™
Movie - How does it work?
Watch the working principle of our BioMatrix NeoFlex™ stent
BioMatrix NeoFlex™
Main brochure

BioMatrix NeoFlex™
Ordering information

1. Data on file at Biosensors International
6. Windecker, S. et al., Biolimus-eluting stent with biodegradable polymer versus Sirolimus-eluting stent with durable polymer for coronary revascularization (LEADERS): a randomised non inferiority trial; The Lancet 2008; 372 No. 9644: 1163-1173.


CAUTION: Please note that the following pages are exclusively reserved for Health Care Professionals in countries with applicable health authority product registrations. To the extent this site contains information intended for use by licensed medical professionals, such materials are not intended to offer professional medical advice. Prior to use, please consult device labeling for prescriptive information and operating instructions. Please contact your Biosensors International representative for availability or the products and registration status.

The law restricts these devices to sale by or on the order of a physician. Prior to use, it is important to read the "Instructions for Use" supplied with these devices for indications, contraindications, suggested procedures, warnings, and precautions.

Biosensors’ interventional cardiology products, including BioMatrix NeoFlex™, BioMatrix™ Alpha, BioFreedom™, BioFreedom™ Ultra, BMX-J® and RISE™ NC, are not available for sale in the United States and certain other countries. ALLEGRA™ is a product of NVT GmbH. Blue Sail Medical Co., Ltd is the ultimate parent company of NVT GmbH and Biosensors International Group, Ltd. and its subsidiaries are collaborating for the commercialization of the ALLEGRA™ device.

BioMatrix NeoFlex, BioMatrix Alpha, BioFreedom, BioFreedom Ultra, BMX-J, Juno, S-Stent and Rise NC are trademarks or registered trademarks of Biosensors International Group, Ltd. ALLEGRA is a trademark or registered trademark of NVT AG. All other cited trademarks are the property of their respective owners.